This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.
Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.
The Pan Mersey Area Prescribing Committee recommends the prescribing of azithromycin tablets in selected high risk patients, when recommended by a respiratory specialist, for the prevention of exacerbations in COPD and bronchiectasis.
NHS England specialised commissining resources: the clinical reference group responsible for cystic fibrosis has published a commissioning policy that defines access to a particular service for a cohort of patients.
The Pan Mersey Area Prescribing Committee recommends the prescribing of ROFLUMILAST tablets (Daxas®▼) following specialist recommendation as an add-on to bronchodilator therapy, for treating severe chronic obstructive pulmonary disease in adults with chronic bronchitis (in accordance with NICE TA461).
The Pan Mersey Area Prescribing Committee recommends the prescribing of TIOTROPIUM inhaler (Spiriva® Respimat®) as an option for patients with poorly controlled asthma who are already on a maintenance dose of inhaled corticosteroid plus a long-acting beta2 agonist inhaler.